Du är här


Orion Oyj: Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2016 AGM of Orion Corporation


Recommendation by the Nomination Committee concerning Board of Directors to be
elected by the 2016 AGM of Orion Corporation

The Nomination Committee of Orion Corporation has given on 27 January 2016 its
recommendation to the Board of Directors of the company for the proposal to
the Annual General Meeting of 2016 concerning the composition of the Board of
Directors to be elected. The Committee recommends that the following proposal
be presented to the AGM of 2016:

The number of Board members would be seven.

Of the present Board members, Sirpa Jalkanen, Timo Maasilta, Mikael
Silvennoinen, Hannu Syrjänen, Heikki Westerlund and Jukka Ylppö would be
re-elected and M.D., Specialist in Internal Medicine Eija Ronkainen would be
elected as a new member for the next term of office.

Hannu Syrjänen would be re-elected as Chairman.

Of the present members, Eero Karvonen has reached the age of 67 and therefore
cannot be elected member of the Board of Directors according to the Articles
of Association.

Essential personal data of Eija Ronkainen:

Born: 1966

Education and profession: M.D., Specialist in Internal Medicine

Spouse: Eero Karvonen

Essential work experience:

* Specialist in Internal Medicine, Hyvinkää Hospital 1999-2002 and 2006-
* Resident Physician, Helsinki University Central Hospital 1995-1999 and
Hyvinkää Hospital 1992-1995

The Nomination Committee also announces as its recommendation that the
following remunerations, which are the same as in the previous year, be paid
to the Board of Directors:

As an annual fee, the Chairman would receive EUR 76,000, the Vice Chairman
would receive EUR 51,000 and the other members would receive EUR 38,000 each.
As a fee for each meeting attended, the Chairman would receive EUR 1,200, the
Vice Chairman would receive EUR 900 and the other members would receive EUR
600 each. The travel expenses of the Board members would be paid in
accordance with previously adopted practice. The aforementioned fees would
also be paid to the Chairmen and to the members of the committees established
by the Board, for each committee meeting attended.

Of the annual fee, 60% would be paid in cash and 40% in Orion Corporation
B-shares, which would be acquired to the members during 29 March-1 April 2016
from the stock exchange in amounts corresponding to EUR 30,400 for the
Chairman, EUR 20,400 for the Vice Chairman and EUR 15,200 for each of the
other members. The part of the annual fee that is to be paid in cash
corresponds to the approximate sum necessary for the payment of the income
taxes on the fees and would be paid no later than 29 April 2016. The annual
fees shall encompass the full term of office of the Board of Directors.

The Nomination Committee has not given its recommendation for the
remunerations to the Board of Directors, but the matter will be proposed by a
shareholder at the AGM.

Of the Nomination Committee members, Kari Jussi Aho and Timo Ritakallio have
not concurred with the Nomination committee's recommendation regarding the
new member of the Board. As to other parts of the recommendation, they
support the recommendation of the Nomination committee.

The Nomination Committee has consisted of the following members: Matti
Kavetvuo, Chairman, Kari Jussi Aho, Erkki Etola, Timo Ritakallio, Seppo
Salonen, Hannu Syrjänen and Jukka Ylppö

Orion Corporation

| Timo Lappalainen Olli Huotari |
|President and CEO |
| SVP, Corporate Functions |
Contact person:

Hannu Syrjänen, Chairman of the Board of Directors of Orion Corporation
phone +358 40 045 4885

Picture of Eija


Orion Corporation
Orionintie 1A, FI-02101 Espoo, Finland

Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical
ingredients and diagnostic tests. The company is continuously developing new
drugs and treatment methods. The core therapy areas of Orion's pharmaceutical
R&D are central nervous system (CNS) disorders, oncology and respiratory for
which Orion developes inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2014 amounted to EUR 1,015 million and the Company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.